SAXO6

Summary

SAXO6 (stabilizer of axonemal microtubules 6, HGNC:29917) is a protein-coding gene on chromosome 12q15, encoding Nuclear protein MDM1 (Q8TC05). Microtubule-binding protein that negatively regulates centriole duplication.

This gene encodes a microtubule-binding nuclear protein that localizes to the centrioles of dividing cells and differentiating multiciliated cells and negatively regulates centriole duplication. The encoded protein is closely associated with the centriole barrel, and resides in the centriole lumen. Naturally-occurring mutations in the orthologous mouse gene are associated with age-related retinal degeneration.

Source: NCBI Gene 56890 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 134 total — 2 pathogenic, 4 likely-pathogenic
• MANE Select transcript: NM_001354969

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29917
Approved symbol	SAXO6
Name	stabilizer of axonemal microtubules 6
Location	12q15
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000111554
Ensembl biotype	protein_coding
OMIM	613813
Entrez	56890

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 10 protein_coding, 5 retained_intron, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000303145, ENST00000357874, ENST00000393543, ENST00000411698, ENST00000430606, ENST00000536313, ENST00000536997, ENST00000538454, ENST00000539972, ENST00000540418, ENST00000540476, ENST00000541087, ENST00000541686, ENST00000545724, ENST00000545964, ENST00000682720, ENST00000890140, ENST00000890141, ENST00000890142

RefSeq mRNA: 11 — MANE Select: NM_001354969 NM_001205028, NM_001205029, NM_001354969, NM_001354970, NM_001354971, NM_001354972, NM_001354973, NM_001354974, NM_001368282, NM_017440, NM_020128

CCDS: CCDS44938, CCDS55841, CCDS55842, CCDS8983, CCDS91723

Canonical transcript exons

ENST00000682720 — 15 exons

Exon	Start	End
ENSE00001632753	68316581	68316610
ENSE00003574601	68313443	68313552
ENSE00003602757	68323073	68323240
ENSE00003605420	68326657	68327021
ENSE00003637228	68331107	68331221
ENSE00003649782	68325441	68325575
ENSE00003675578	68321525	68321628
ENSE00003690855	68313644	68313753
ENSE00003717084	68321347	68321446
ENSE00003725461	68302620	68302872
ENSE00003728211	68296923	68296982
ENSE00003741375	68316078	68316253
ENSE00003741481	68314948	68315265
ENSE00003918116	68294566	68295366
ENSE00003921615	68332228	68332362

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 95.56.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.4014 / max 989.8251, expressed in 1702 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
131968	7.3106	1631
131969	2.7510	1126
131967	0.2787	128
131966	0.0611	18

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	95.56	gold quality
choroid plexus epithelium	UBERON:0003911	94.58	gold quality
ventricular zone	UBERON:0003053	94.46	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.32	gold quality
epithelium of bronchus	UBERON:0002031	91.99	gold quality
right uterine tube	UBERON:0001302	91.91	gold quality
oocyte	CL:0000023	91.16	gold quality
bronchus	UBERON:0002185	91.04	gold quality
calcaneal tendon	UBERON:0003701	91.00	gold quality
secondary oocyte	CL:0000655	90.28	gold quality
sural nerve	UBERON:0015488	90.22	gold quality
mucosa of paranasal sinus	UBERON:0005030	90.13	gold quality
sigmoid colon	UBERON:0001159	89.88	gold quality
epithelium of nasopharynx	UBERON:0001951	89.59	gold quality
nasopharynx	UBERON:0001728	89.57	gold quality
body of uterus	UBERON:0009853	88.84	gold quality
monocyte	CL:0000576	88.42	gold quality
adenohypophysis	UBERON:0002196	88.37	gold quality
ganglionic eminence	UBERON:0004023	88.03	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.89	gold quality
left uterine tube	UBERON:0001303	87.84	gold quality
mononuclear cell	CL:0000842	87.80	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	87.59	gold quality
leukocyte	CL:0000738	87.48	gold quality
lower esophagus muscularis layer	UBERON:0035833	87.45	gold quality
lower esophagus	UBERON:0013473	87.42	gold quality
pituitary gland	UBERON:0000007	87.41	gold quality
pigmented layer of retina	UBERON:0001782	86.65	gold quality
seminal vesicle	UBERON:0000998	86.30	gold quality
bone marrow cell	CL:0002092	86.12	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.27

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

61 targeting SAXO6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-5003-5P	99.61	69.13	1624
HSA-MIR-7159-3P	99.51	70.17	1920
HSA-MIR-3128	99.50	67.85	1258
HSA-MIR-513C-5P	99.50	68.42	1730

Literature-anchored findings (GeneRIF, showing 2)

• Not associated with age-related retinal degeneration. (PMID:18805803)
• Authorse propose that MDM1 is a negative regulator of centriole duplication and that its function is mediated through microtubule binding. (PMID:26337392)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mdm1	ENSDARG00000045675
mus_musculus	Mdm1	ENSMUSG00000020212
rattus_norvegicus	Mdm1	ENSRNOG00000007286

Protein

Protein identifiers

Nuclear protein MDM1 — Q8TC05 (reviewed: Q8TC05)

All UniProt accessions (6): Q8TC05, A0A804HIJ5, F5H529, F5H804, H0Y301, H0YGX6

UniProt curated annotations — full annotation on UniProt →

Function. Microtubule-binding protein that negatively regulates centriole duplication. Binds to and stabilizes microtubules.

Subcellular location. Nucleus. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Centriole.

Similarity. Belongs to the MDM1 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8TC05-1	1	yes
Q8TC05-2	2
Q8TC05-3	3
Q8TC05-4	4

RefSeq proteins (11): NP_001191957, NP_001191958, NP_001341898, NP_001341899, NP_001341900, NP_001341901, NP_001341902, NP_001341903, NP_001355211, NP_059136, NP_064513 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029136	MDM1	Family

Pfam: PF15501

UniProt features (38 total): modified residue 9, splice variant 6, compositionally biased region 5, sequence variant 4, mutagenesis site 4, short sequence motif 4, region of interest 3, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TC05-F1	54.47	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 83, 123, 126, 242, 263, 314, 560, 584, 648

Mutagenesis-validated functional residues (4):

Position	Phenotype
9–15	loss of microtubule binding, no loss of centrosomal localization, little effect on microtubule stability, loss of abilit
189–195	loss of microtubule binding, no loss of centrosomal localization, little effect on microtubule stability, loss of abilit
232–238	loss of microtubule binding, no loss of centrosomal localization, little effect on microtubule stability, loss of abilit
306–312	loss of microtubule binding, no loss of centrosomal localization, little effect on microtubule stability, loss of abilit

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 253 (showing top): BROWNE_HCMV_INFECTION_6HR_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, FISCHER_G1_S_CELL_CYCLE, TTTGTAG_MIR520D, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, AATGGAG_MIR136, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_NEGATIVE_REGULATION_OF_ORGANELLE_ASSEMBLY, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_REGULATION_OF_CENTRIOLE_REPLICATION, GOBP_CENTRIOLE_ASSEMBLY, MODULE_205, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE

GO Biological Process (2): negative regulation of centriole replication (GO:0046600), retina development in camera-type eye (GO:0060041)

GO Molecular Function (2): microtubule binding (GO:0008017), protein binding (GO:0005515)

GO Cellular Component (8): nucleus (GO:0005634), centrosome (GO:0005813), centriole (GO:0005814), cytosol (GO:0005829), microtubule (GO:0005874), centriolar satellite (GO:0034451), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
microtubule organizing center	2
intracellular membraneless organelle	2
centriole replication	1
negative regulation of centrosome duplication	1
regulation of centriole replication	1
negative regulation of organelle assembly	1
camera-type eye development	1
anatomical structure development	1
tubulin binding	1
binding	1
intracellular membrane-bounded organelle	1
centriole	1
cytoplasm	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
centrosome	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

408 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SAXO6	SNX14	Q9Y5W7	694
SAXO6	MYF6	P23409	678
SAXO6	MDM2	Q00987	647
SAXO6	SNX13	Q9Y5W8	615
SAXO6	SNX25	Q9H3E2	614
SAXO6	ACSL3	O95573	567
SAXO6	STARD3NL	O95772	566
SAXO6	SNX19	Q92543	545
SAXO6	CDKN2A	P42771	448
SAXO6	CDK4	P11802	402
SAXO6	SLC35E3	Q7Z769	383
SAXO6	IFNG	P01579	373
SAXO6	FILIP1L	Q4L180	368
SAXO6	BSCL2	Q96G97	355
SAXO6	SOFU1	Q96L11	350

IntAct

18 interactions, top by confidence:

A	B	Type	Score
MDM1	POC1A	psi-mi:“MI:0915”(physical association)	0.590
MDM1	HOMER3	psi-mi:“MI:0915”(physical association)	0.560
CCDC57	MDM1	psi-mi:“MI:0915”(physical association)	0.560
MAGEA4	MAGEB16	psi-mi:“MI:0914”(association)	0.530
Poc1a	SQSTM1	psi-mi:“MI:0914”(association)	0.350
CBX4		psi-mi:“MI:0914”(association)	0.350
CDK5RAP2	SPTBN2	psi-mi:“MI:0914”(association)	0.350
CEP63	CIBAR1	psi-mi:“MI:0914”(association)	0.350
S100P	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
HDAC8	SEC16A	psi-mi:“MI:0914”(association)	0.350
MDM1	HOMER3	psi-mi:“MI:0915”(physical association)	0.000
MDM1	CCDC57	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): MDM1 (Affinity Capture-MS), MDM1 (Affinity Capture-MS), MDM1 (Reconstituted Complex), MDM1 (Affinity Capture-MS), POC1A (Affinity Capture-MS), MDM1 (Two-hybrid), CCDC57 (Two-hybrid), MDM1 (Affinity Capture-RNA), POC1A (Affinity Capture-MS), MDM1 (Affinity Capture-MS), MDM1 (Affinity Capture-MS), MDM1 (Proximity Label-MS), MDM1 (Proximity Label-MS), MDM1 (Affinity Capture-RNA), MDM1 (Proximity Label-MS)

ESM2 similar proteins: A0A1W2P884, A2RUB6, A7E3D8, A8MT70, B0CM36, B2RYR0, F1PZQ5, O95447, Q0IIM1, Q0P5X1, Q2KHM9, Q2T9X8, Q4KLH6, Q4R3Q7, Q4R6Q9, Q5NVK0, Q5R7F8, Q5RBD6, Q5RBY6, Q5RC32, Q5RD75, Q5SZL2, Q5TB80, Q5TID7, Q5VX52, Q5XI03, Q6A000, Q6NS45, Q6NZK5, Q6ZPR1, Q6ZQ06, Q7Z4H7, Q80VP2, Q80XJ2, Q80ZU5, Q86T90, Q86YF9, Q8BMD2, Q8IYW5, Q8N0Z3

Diamond homologs: Q5PQN4, Q5RC32, Q5RHU7, Q5ZMW6, Q8TC05, Q9D067

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

134 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	4
Uncertain significance	93
Likely benign	7
Benign	2

Top pathogenic / likely-pathogenic (6)

Variant ID	HGVS	Classification
4813667	NM_001354969.2(SAXO6):c.2T>C (p.Met1Thr)	Pathogenic
4813668	NM_001354969.2(SAXO6):c.1038del (p.Glu348fs)	Pathogenic
4813669	NM_001354969.2(SAXO6):c.1240A>T (p.Lys414Ter)	Likely pathogenic
4813670	NM_001354969.2(SAXO6):c.868A>T (p.Lys290Ter)	Likely pathogenic
4813671	NM_001354969.2(SAXO6):c.1048C>T (p.Arg350Ter)	Likely pathogenic
4813672	NM_001354969.2(SAXO6):c.1750-1G>C	Likely pathogenic

SpliceAI

2569 predictions. Top by Δscore:

Variant	Effect	Δscore
12:68295364:CATCT:C	acceptor_loss	1.0000
12:68295366:TC:T	acceptor_loss	1.0000
12:68295367:C:CA	acceptor_loss	1.0000
12:68295368:T:A	acceptor_loss	1.0000
12:68296984:T:C	acceptor_gain	1.0000
12:68313438:TTTAC:T	donor_loss	1.0000
12:68313439:TTA:T	donor_loss	1.0000
12:68313440:TAC:T	donor_loss	1.0000
12:68313441:A:C	donor_loss	1.0000
12:68313549:CCAC:C	acceptor_gain	1.0000
12:68313550:CAC:C	acceptor_gain	1.0000
12:68313550:CACC:C	acceptor_gain	1.0000
12:68313552:CCTG:C	acceptor_loss	1.0000
12:68313553:C:CC	acceptor_gain	1.0000
12:68313553:CTG:C	acceptor_loss	1.0000
12:68313554:T:A	acceptor_loss	1.0000
12:68313647:CAG:C	donor_gain	1.0000
12:68314947:CCCTT:C	donor_gain	1.0000
12:68314962:ATCTG:A	donor_gain	1.0000
12:68315041:T:TA	donor_gain	1.0000
12:68321519:ACAT:A	donor_loss	1.0000
12:68321520:CAT:C	donor_loss	1.0000
12:68321521:ATA:A	donor_loss	1.0000
12:68321522:TACC:T	donor_loss	1.0000
12:68321523:A:AC	donor_gain	1.0000
12:68321523:AC:A	donor_gain	1.0000
12:68321524:C:CC	donor_gain	1.0000
12:68321524:CC:C	donor_gain	1.0000
12:68321527:AAG:A	donor_gain	1.0000
12:68321556:T:TA	donor_gain	1.0000

AlphaMissense

4736 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:68316146:C:A	W371C	0.995
12:68316146:C:G	W371C	0.995
12:68316148:A:G	W371R	0.994
12:68316148:A:T	W371R	0.994
12:68316194:A:C	F355L	0.994
12:68316194:A:T	F355L	0.994
12:68316195:A:G	F355S	0.994
12:68316196:A:G	F355L	0.994
12:68321416:A:C	F312L	0.994
12:68321416:A:T	F312L	0.994
12:68321418:A:G	F312L	0.994
12:68316180:A:G	L360P	0.992
12:68321379:A:G	W325R	0.990
12:68321379:A:T	W325R	0.990
12:68316232:C:G	A343P	0.989
12:68302630:A:C	F654L	0.986
12:68302630:A:T	F654L	0.986
12:68302632:A:G	F654L	0.986
12:68313675:C:A	R526S	0.986
12:68313675:C:G	R526S	0.986
12:68316243:A:G	L339P	0.986
12:68313540:A:G	L541S	0.985
12:68325489:A:C	F195L	0.985
12:68325489:A:T	F195L	0.985
12:68325491:A:G	F195L	0.985
12:68316240:C:G	R340P	0.984
12:68313543:A:T	V540D	0.983
12:68331213:A:C	S9R	0.982
12:68331213:A:T	S9R	0.982
12:68331215:T:G	S9R	0.982

dbSNP variants (sampled 300 via entrez): RS1000044607 (12:68303994 T>A,C), RS1000072076 (12:68311142 C>T), RS1000111893 (12:68305439 G>A), RS1000144359 (12:68305141 C>T), RS1000326555 (12:68312079 C>T), RS1000330718 (12:68318609 A>T), RS1000366255 (12:68298763 C>G,T), RS1000448538 (12:68331046 G>A), RS1000559468 (12:68325030 T>A,C), RS1000652492 (12:68310762 C>T), RS1000734277 (12:68299111 G>A,C), RS1000736385 (12:68332326 C>A,G,T), RS1000973046 (12:68300035 G>A), RS1001046013 (12:68305355 A>G,T), RS1001107350 (12:68307070 T>A)

Disease associations

OMIM: gene MIM:613813 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (3): retinal disorder (MONDO:0005283), neurodevelopmental disorder (MONDO:0700092), schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001419_1	Temperament (bipolar disorder)	4.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004365	personality trait

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
D012164	Retinal Diseases	C11.768

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, affects expression, affects cotreatment, decreases methylation	3
Air Pollutants	decreases expression, increases abundance, increases expression	2
Valproic Acid	increases expression	2
Cyclosporine	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
potassium perchlorate	decreases expression	1
trichostatin A	decreases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
butyraldehyde	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
pentanal	decreases expression	1
tamibarotene	decreases expression	1
bisphenol S	decreases methylation	1
NSC 689534	affects binding, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Arsenic	decreases expression, increases abundance, affects cotreatment	1
Azathioprine	decreases expression	1
Calcitriol	increases expression	1
Cisplatin	increases expression	1
Copper	affects binding, decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Folic Acid	decreases expression	1

Clinical trials (associated diseases)

529 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety